- Home
- IRON vs LGND Comparison
IRON vs LGND Comparison
Compare IRON & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- LGND
- Stock Information
- Founded
- IRON 2017
- LGND 1987
- Country
- IRON United States
- LGND United States
- Employees
- IRON N/A
- LGND 68
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- LGND Health Care
- Exchange
- IRON Nasdaq
- LGND Nasdaq
- Market Cap
- IRON 3.4B
- LGND 3.2B
- IPO Year
- IRON N/A
- LGND 1992
- Fundamental
- Price
- IRON $89.84
- LGND $200.98
- Analyst Decision
- IRON Strong Buy
- LGND Strong Buy
- Analyst Count
- IRON 12
- LGND 8
- Target Price
- IRON $108.83
- LGND $144.71
- AVG Volume (30 Days)
- IRON 531.4K
- LGND 139.7K
- Earning Date
- IRON 11-06-2025
- LGND 08-05-2025
- Dividend Yield
- IRON N/A
- LGND N/A
- EPS Growth
- IRON N/A
- LGND N/A
- EPS
- IRON N/A
- LGND N/A
- Revenue
- IRON N/A
- LGND $181,488,000.00
- Revenue This Year
- IRON N/A
- LGND $18.41
- Revenue Next Year
- IRON N/A
- LGND $18.87
- P/E Ratio
- IRON N/A
- LGND N/A
- Revenue Growth
- IRON N/A
- LGND 53.40
- 52 Week Low
- IRON $30.82
- LGND $81.74
- 52 Week High
- IRON $95.95
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- IRON 64.84
- LGND 60.66
- Support Level
- IRON $83.00
- LGND $198.52
- Resistance Level
- IRON $90.39
- LGND $212.49
- Average True Range (ATR)
- IRON 3.70
- LGND 8.11
- MACD
- IRON -0.40
- LGND -0.04
- Stochastic Oscillator
- IRON 74.77
- LGND 63.03
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.